Psilocybin for Addiction: What the Clinical Trials Found

Addiction is one of the most treatment-resistant conditions in medicine. Relapse rates for alcohol, tobacco, and opioid addiction remain stubbornly high despite decades of pharmacological and behavioral interventions. Psilocybin has produced some of the most striking results in addiction research — results that have surprised even skeptical researchers.

Tobacco Addiction: The Johns Hopkins Study

A 2014 Johns Hopkins pilot study gave 15 smokers two or three psilocybin sessions (20–30mg) combined with cognitive behavioral therapy for smoking cessation. At 6-month follow-up, 80% of participants had quit smoking — compared to 35% for nicotine replacement therapy and 22% for varenicline (Chantix), the most effective pharmaceutical option. At 12-month follow-up, 67% remained abstinent. These are extraordinary numbers for tobacco cessation.

Further Research on Psilocybin for Smoking Cessation

Building on the initial success, further research has continued to explore psilocybin's potential in smoking cessation. A more recent pilot randomized clinical trial compared psilocybin with nicotine patches for smoking cessation [Johnson et al., 2026]. This study found that at six months, 40.5% of participants in the psilocybin group achieved biochemically verified prolonged abstinence, suggesting continued strong efficacy. Johns Hopkins has also received grants to further investigate psilocybin's role in smoking cessation, indicating ongoing scientific interest and validation of earlier findings [Hopkins Medicine, 2021]. The mechanism often involves psilocybin's ability to improve cognitive control and decrease the anticipation of withdrawal relief from smoking [ClinicalTrials.gov, NCT05452772].

Alcohol Use Disorder: NYU and UCSF Trials

A 2022 JAMA Psychiatry study randomized 93 adults with alcohol use disorder to receive either two psilocybin sessions or antihistamine (active placebo). The psilocybin group showed significantly greater reductions in heavy drinking days (from 52% to 10% of days) compared to placebo (from 52% to 24%). These effects persisted at 8-month follow-up.

Expanding on Psilocybin for Alcohol Use Disorder

The NYU Langone study, published in JAMA Psychiatry, highlighted that two doses of psilocybin combined with psychotherapy reduced alcohol consumption by an impressive 83% among heavy drinkers [Bogenschutz et al., 2022; NYU Langone, 2022]. This reduction was measured as a percentage of heavy drinking days, with the psilocybin group reporting only 9.7% heavy drinking days during the 32-week double-blind period, compared to 23.6% in the diphenhydramine (placebo) group [Bogenschutz et al., 2022]. Further studies are also underway to assess whether a single dose of psilocybin with brief psychotherapy can reduce relapse rates and alcohol use in AUD patients [Rieser et al., 2025]. Research also suggests that psilocybin might diminish preference for alcohol cues and engage inhibitory control centers in the brain [Pagni et al., 2024].

Opioid Use Disorder: Emerging Research

While research on psilocybin for opioid use disorder (OUD) is still in earlier stages compared to tobacco and alcohol, preliminary findings and ongoing trials show promise. Johns Hopkins is conducting upcoming studies to determine the effectiveness of psilocybin as a new therapy for opioid addiction [Hopkins Medicine, Psychedelics Research]. The therapeutic potential is rooted in psilocybin's ability to induce neuroplasticity and alter entrenched behavioral patterns, which are critical in breaking the cycle of opioid dependence. The profound shifts in perspective and self-concept often reported by individuals undergoing psilocybin-assisted therapy could be particularly beneficial for addressing the psychological components of OUD.

Why Psilocybin Works for Addiction

Addiction involves rigid, compulsive behavioral patterns driven by hyperactivated reward circuits and impaired prefrontal control. Psilocybin disrupts these patterns through neuroplasticity — creating a window during which new, non-addictive patterns can form. The "mystical experience" quality of psilocybin sessions also appears to produce profound shifts in values and self-concept that support sustained behavior change.

Neurobiological Mechanisms

Psilocybin's primary mechanism of action involves its agonistic activity at the 5-HT2A serotonin receptors in the brain [Johnson et al., 2016]. This interaction leads to a cascade of effects, including increased neuroplasticity, which refers to the brain's ability to reorganize itself by forming new neural connections [Psilocybin Neuroplasticity]. This enhanced plasticity can help individuals break free from rigid thought patterns and behaviors associated with addiction. Furthermore, psilocybin can transiently reduce activity in the default mode network (DMN), a brain network associated with self-referential thought and rumination. A reduction in DMN activity can lead to a more flexible and open state of mind, facilitating introspection and new perspectives on addictive behaviors [Carhart-Harris et al., 2014].

Psychological and Experiential Factors

Beyond neurobiology, the profound psychological experiences often induced by psilocybin play a crucial role. These experiences, frequently described as mystical or spiritual, can lead to significant shifts in values, priorities, and self-perception [Griffiths et al., 2006]. For individuals struggling with addiction, such experiences can provide a new sense of purpose, meaning, and connection, which are vital for sustained recovery. The therapeutic setting, often involving guided preparation and integration sessions, helps individuals process these experiences and translate insights into lasting behavioral changes. This combination of pharmacological action and psychological support is what makes psilocybin-assisted therapy particularly effective [Bogenschutz & Johnson, 2020].

Comparative Efficacy: Psilocybin vs. Traditional Treatments

The efficacy rates observed in psilocybin trials for addiction are often higher than those seen with conventional treatments. For instance, the 80% abstinence rate in the Johns Hopkins tobacco study significantly surpasses the 35% for nicotine replacement therapy and 22% for varenicline [Johnson et al., 2014]. Similarly, for alcohol use disorder, psilocybin-assisted therapy has shown superior reductions in heavy drinking days compared to placebo [Bogenschutz et al., 2022]. This suggests that psilocybin offers a unique and powerful therapeutic approach, especially for conditions that have historically been resistant to treatment. It's important to note that psilocybin therapy is typically administered in conjunction with psychotherapy, which is a critical component of its success [Microdosing vs Antidepressants Side Effects].

The Role of Shrooomz in Supporting Well-being

While Shrooomz focuses on functional mushroom gummies and microdosing products that do not contain psilocybin, we are committed to advancing overall well-being and supporting research into innovative therapeutic approaches. Our products, such as those containing Lion's Mane, Reishi, and Cordyceps, are designed to support cognitive function, stress reduction, and overall vitality, complementing a holistic approach to health. We believe in the power of natural compounds to enhance human potential and are excited by the broader implications of psychedelic research for mental health and addiction recovery.

Clinical Trial Data Overview

Future Directions and Challenges

The promising results from clinical trials have paved the way for larger, more comprehensive studies. Researchers are actively exploring optimal dosing regimens, therapeutic protocols, and the long-term efficacy of psilocybin-assisted therapy for various addictions. However, challenges remain, including regulatory hurdles, the need for standardized training for therapists, and ensuring equitable access to these treatments once approved. The potential for psilocybin to revolutionize addiction treatment is immense, but careful and rigorous research is essential to fully realize its benefits.

Frequently Asked Questions (FAQ)

Q: Is psilocybin legal for addiction treatment?

A: Currently, psilocybin is classified as a Schedule I substance in many countries, including the United States, meaning it has a high potential for abuse and no accepted medical use. However, there is a growing movement towards decriminalization and medical legalization, with some states and cities enacting reforms. Clinical trials operate under specific regulatory approvals, and widespread legal access for addiction treatment is still pending further research and policy changes.

Q: How does psilocybin therapy differ from traditional addiction treatments?

A: Psilocybin therapy differs significantly from traditional treatments by focusing on a single or a few high-dose sessions within a psychotherapeutic framework, aiming to induce profound psychological experiences. Traditional treatments often involve long-term medication regimens, behavioral therapies, and support groups without the psychedelic component. While both aim for recovery, psilocybin therapy seeks to create a transformative experience that can rapidly shift perspectives and break entrenched addictive patterns, often with sustained effects after just a few sessions.

Q: Are there any risks associated with psilocybin-assisted therapy for addiction?

A: Like any medical intervention, psilocybin-assisted therapy carries potential risks. These can include psychological distress during the psilocybin experience, such as anxiety or paranoia, especially if not administered in a controlled and supportive environment. Physical risks are generally low in healthy individuals but can include temporary increases in heart rate and blood pressure. It is crucial that psilocybin therapy is conducted under the supervision of trained professionals in a clinical setting to mitigate these risks and ensure patient safety.

Q: Can psilocybin be used to treat all types of addiction?

A: While research has shown promising results for tobacco and alcohol use disorders, the efficacy of psilocybin for other addictions, such as opioid, cocaine, or gambling addiction, is still under investigation. The underlying mechanisms of addiction can vary, and what works for one substance may not be equally effective for another. Ongoing clinical trials are exploring the broader applicability of psilocybin-assisted therapy across the spectrum of addictive behaviors.

References

1. [Johnson et al., 2014] Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. Link
2. [Johnson et al., 2026] Johnson, M. W. (2026). Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. JAMA Network Open. Link
3. [Hopkins Medicine, 2021] Johns Hopkins Receives Grant for Psilocybin Research in Smoking Cessation. (2021, November 18). Hopkins Medicine. Link
4. [ClinicalTrials.gov, NCT05452772] 5-HT2A Agonist Psilocybin for Smoking Cessation. ClinicalTrials.gov. Link
5. [Bogenschutz et al., 2022] Bogenschutz, M. P., Ross, S., Carroll, J. J., Parides, M. K., Rodriguez, D., Ayele, T., ... & Forcehimes, A. A. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo With Psychotherapy for Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 79(10), 953-962. Link
6. [NYU Langone, 2022] Psychedelic Drug Therapy May Help Treat Alcohol Addiction. (2022, August 24). NYU Langone. Link
7. [Rieser et al., 2025] Rieser, N. M., et al. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder. ScienceDirect. Link
8. [Pagni et al., 2024] Pagni, B. A., et al. (2024). Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study. Scientific Reports, 14(1), 52967-8. Link
9. [Hopkins Medicine, Psychedelics Research] Psychedelics Research and Psilocybin Therapy. Hopkins Medicine. Link
10. [Carhart-Harris et al., 2014] Carhart-Harris, R. L., et al. (2014). The default mode network in psilocybin-assisted psychotherapy. Brain, 137(Pt 8), 2309-2319. Link
11. [Griffiths et al., 2006] Griffiths, R. R., et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283. Link
12. [Bogenschutz & Johnson, 2020] Bogenschutz, M. P., & Johnson, M. W. (2020). Classic psychedelics in the treatment of addictions. Pharmacological Reviews, 72(3), 577-607. Link
13. [Jensen et al., 2025] Jensen, M. E., et al. (2025). Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study. Journal of Psychopharmacology. Link

• Microdosing Mushrooms for Depression
• Psilocybin PTSD Research
• Psilocybin Neuroplasticity: How Mushrooms Rewire the Brain
• Microdosing vs. Antidepressants: Side Effects